3-Azetidineacetonitrile, 1-(cyclopropylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-

Chemical Properties

Density	1.69±0.1 g/cm3(Predicted)
storage temp.	Store at -20°C
solubility	DMSO : 250 mg/mL (652.01 mM; Need ultrasonic)
pka	11.66±0.50(Predicted)
form	Solid
color	White to off-white
InChI	InChI=1S/C17H17N7O2S/c18-5-4-17(9-23(10-17)27(25,26)13-1-2-13)24-8-12(7-22-24)15-14-3-6-19-16(14)21-11-20-15/h3,6-8,11,13H,1-2,4,9-10H2,(H,19,20,21)
InChIKey	RVOUEXFKIYNODQ-UHFFFAOYSA-N
SMILES	N1(S(C2CC2)(=O)=O)CC(N2C=C(C3N=CN=C4NC=CC4=3)C=N2)(CC#N)C1

Send Inquriy

Animal Model:	Oclacitinib-induced canine atopic dermatitis (cAD) dog model^[2]
Dosage:	0.6-0.8 mg/kg
Administration:	Oral gavage (p.o.), once daily, up to 112 days
Result:	Within 14 days：showed similar efficacy to Oclacitinib in reducing pruritus and skin lesions. By day 28：continued to decrease PVAS scores which was increased in the Oclacitinib group. From days 28 to 112: Caused that mean PVAS and CADESI-04 scores were significantly lower in the Ilunocitinib group than in the Oclacitinib group (p ≤ 0.003 and p ≤ 0.023). At day 112: Caused that 77% of Ilunocitinib-treated dogs achieved clinical remission of pruritus (PVAS <2) compared to 53% in the Oclacitinib group.